Search results
Results From The WOW.Com Content Network
C3 convertase (C4bC2b, formerly C4b2a) belongs to family of serine proteases and is necessary in innate immunity as a part of the complement system which eventuate in opsonisation of particles, release of inflammatory peptides, C5 convertase formation and cell lysis.
In the fields of databases and transaction processing (transaction management), a schedule (or history) of a system is an abstract model to describe the order of executions in a set of transactions running in the system. Often it is a list of operations (actions) ordered by time, performed by a set of transactions that are executed together in ...
Cleavage of Arg-Ser bond in complement component C3 alpha-chain to yield C3a and C3b, and Arg- bond in complement component C5 alpha-chain to yield C5a and C5b. This enzyme is a bimolecular complex of complement fragment Bb with either C3b or cobra venom factor.
Bb remains bound to C3(H 2 O) to form C3(H 2 O)Bb. This complex is also known as a fluid-phase C3-convertase. This convertase, the alternative pathway C3-convertase, although only produced in small amounts, can cleave multiple C3 proteins into C3a and C3b. The complex is believed to be unstable until it binds properdin, a serum protein. The ...
Complement component 3, often simply called C3, is a protein of the immune system that is found primarily in the blood. It plays a central role in the complement system of vertebrate animals and contributes to innate immunity. In humans it is encoded on chromosome 19 by a gene called C3. [5] [6]
This activated C1 complex cleaves C4 and C2 forming a C4bC2b complex that covalently bonds to the surface of the microbe and functions as a C3 convertase, binding and cleaving C3 into C3a and C3b. Binding of a C3b molecule to the C4bC2b complex (C4b2b3b) results in the formation of a C5 convertase, which cleaves C5 into C5a and C5b.
For premium support please call: 800-290-4726 more ways to reach us
This is the list of Schedule III controlled substances in the United States as defined in section 202 of the Controlled Substances Act (21 U.S.C. § 812) and 21 CFR 1308.13. The following findings are required for substances to be placed in this schedule: